PDS Biotechnology (PDSB) Research & Development (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Research & Development came in at $4.4 million in Q4 2025, down 2.74% YoY from $4.5 million in Q4 2024, and down 3.73% on a QoQ basis from $4.6 million in Q3 2025.
PDS Biotechnology (PDSB) Research & Development (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Research & Development data on file, last reported at $4.4 million in Q4 2025.
- Quarterly Research & Development fell 2.74% year-over-year to $4.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.0 million (down 15.69% YoY) and the FY2025 annual result came in at $19.0 million, down 15.69% from the prior year.
- Research & Development slipped to $4.4 million in Q4 2025, from $4.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $16.2 million in Q4 2022 to a low of $1.4 million in Q1 2021.
- A 5-year average of $5.5 million and a median of $4.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 376.65% — and 2023, when it plunged 53.79%.
- Tracing PDSB's Research & Development over 5 years: stood at $3.4 million in 2021, then surged by 376.65% to $16.2 million in 2022, then sank by 53.79% to $7.5 million in 2023, then plunged by 39.33% to $4.5 million in 2024, then declined by 2.74% to $4.4 million in 2025.
- The last three Research & Development figures came in at $4.4 million (Q4 2025), $4.6 million (Q3 2025), and $4.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | PDS Biotechnology | 11.58 Mn | 11.58 Mn | - | 3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.27 Mn |
| Dec 31, 2025 | 4.41 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | 4.53 Mn |
| Sep 30, 2024 | 6.80 Mn |
| Jun 30, 2024 | 4.53 Mn |
| Mar 31, 2024 | 6.70 Mn |
| Dec 31, 2023 | 7.47 Mn |
| Sep 30, 2023 | 6.45 Mn |
| Jun 30, 2023 | 8.00 Mn |
| Mar 31, 2023 | 5.84 Mn |
| Dec 31, 2022 | 16.16 Mn |
| Sep 30, 2022 | 4.35 Mn |
| Jun 30, 2022 | 3.76 Mn |
| Mar 31, 2022 | 5.16 Mn |
| Dec 31, 2021 | 3.39 Mn |
| Sep 30, 2021 | 3.69 Mn |
| Jun 30, 2021 | 2.76 Mn |